
BIOTECHNOLOGY


MARKET SIZE

India Biotechnology industry valuation (US$ billion)




APPROVALS

Number of biologics and biosimilars approved in India




KEY TRENDS

Clinical trials market in India (US$ billion)



Medical device market in India (US$ billion)



GOVERNMENT INITIATIVES



Make in India



Biotech Parks

National Biopharma Mission

ADVANTAGE INDIA

- **Skilled human capital:** With a total population of 1.4 billion, 47% being under the age of 25, India has a large pool of young and skilled workforce. India has a large reservoir of scientific human resources, including scientists and engineers.
- **Government Support:** In February 2026, the Government of India introduced the Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) initiative under the Union Budget 2026-27, a five-year scheme with an outlay of Rs. 10,000 crore (US$ 1.13 billion) aimed at strengthening India's position as a global manufacturing hub for biologics and biosimilars. Supported by the Department of Biotechnology (DBT), the ecosystem has benefited from enhanced research infrastructure, industry collaborations and innovation-driven initiatives aligned with national programmes such as AatmaNirbhar Bharat, Startup India and Make in India.
- **FDI Policy**: 100% under automatic route for greenfield projects for pharmaceuticals; 100% under automatic route is allowed for the manufacturing of medical devices.
- **Epidemiological factors**: India's senior citizen population is projected to surge to around 230 million by 2036, making up about 15% of the total population. The country is expected to have around 134 million people with diabetes by 2045, while non-communicable diseases (NCDs) currently account for approximately 63% of all deaths in the country.

Copyright © 2026 IBEF. All rights reserved.